2021年国药集团一致药业股份有限公司中报

China National Accord Medicines Corporation Ltd. Semi-Annual Report 2021 August 2021 Section I. Important Notice, Contents and Interpretation Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents. Lin Zhaoxiong, Principal of the Company, Gu Guolin, person in charger of accounting works and Wang Ying, person in charge of accounting organ (accounting principal) hereby confirm that the Financial Report of Semi- Annual Report 2021 is authentic, accurate and complete. All directors are attended the Board Meeting for report deliberation. The Company plans not to pay cash dividends, bonus and carry out capitalizing of common reserves. Contents Section I Importan Notice, Contents and Interpretation...... 2 Section II Company Profile and Main Financial Indexes......6 Section III Management Discussion and Aanalysis......9 Section IV Corporate Governance......31 Section V Enviornmental and Social Responsibility......33 Section VI Important Events......37 Section VII Changes in Shares and Particular about Shareholders......70 Section VIII Preferred Stock...... 76 Section IX Corporate Bonds......77 Section X Financial Report......78 DocumentsAvailable for Reference I.The financial statements carried with the signature and seals of legal representative, person in charger of accounting works and person in charge of accounting organ; II.Original text of all documents of the Company as well as the manuscript of the announcement disclosed in the reporting period on Juchao Website. III. Text of the Semi-Annual Report 2021 bearing the signature of the legal representative. Interpretation Items Refers to Contents Listed Company, Company, the Company, Refers to China National Accord Medicines Corporation Ltd. SinopharmAccord, the Group SINOPHARM Refers to China National Accord Medicines Corporation Ltd. Sinopharm Holding Refers to Sinopharm Group Co., Ltd, Controlling shareholder of the Company Company Law Refers to Company Law of the People’s Republic of China Securities Law Refers to Securities Law of the People’s Republic of China Yuan, 10 thousand Yuan, 100 million Yuan Refers to RMB, RMB 10 thousand, RMB 100 million Terminology: Refers to SPD hospital logistics supply chain extension business, IVD 4D business Refers to diagnostic reagent business, CSSD disinfection service, and MWD equipment life cycle management business GPO Refers to Group purchasing organizations Abbreviation: Refers to Sinopharm Holding Guangzhou Refers to Sinopharm Holding Guangzhou Co., Ltd. Guoda Drugstore Refers to Sinopharm Holding Guoda Drugstore Co., Ltd. Sinopharm Holding Guangxi Refers to Sinopharm Holding Guangxi Co., Ltd. China National Zhijun Refers to China National Zhijun (Shenzhen) Pharmaceutical Co., Ltd. Zhijun Pharmacy Trade Refers to Shenzhen Zhijun Pharmacy Trade Co., Ltd. Zhijun Pingshan Refers to China National Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. Main Luck Pharmaceuticals Refers to Shenzhen Main Luck Pharmaceuticals Inc. Section II Company Profile and Main Financial Indexes I. Company profile Short form of the stock SinopharmAccord,Accord B Stock code 000028, 200028 Stock exchange for listing Shenzhen Stock Exchange Name of the Company (in Chinese) 国药集团一致药业股份有限公司 Short form of the Company (in Chinese if applicable) 国药一致 Foreign name of the Company (if applicable) China NationalAccord Medicines Corporation Ltd. Short form of foreign name of the Company (if applicable) SinopharmAccord Legal representative Lin Zhaoxiong II. Person/Way to contact Secretary of the Board Name Chen Changbing Contact add. Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province Tel. +(86)755 25875195 Fax. +(86)755 25195435 E-mail gyyzinvestor@sinopharm.com III.Others 1.Way of contact Whether registrations address, offices address and codes as well as website and email of the Company changed in reporting period or not □Applicable √ Not applicable Registrations address, offices address and codes as well as website and email of the Company has no change in reporting period, found more details inAnnual Report 2020. 2. Information disclosure and preparation place Whether information disclosure and preparation place changed in reporting period or not □Applicable √ Not applicable The newspaper appointed for information disclosure, website for semi-annual report publish appointed by CSRC and preparation place for semi-annual report have no change in reporting period, found more details in Annual Report 2020 IV. Main accounting data and financial indexes Whether it has retroactive adjustment or re-statement on previous accounting data □Yes √No Current period Same period of last year Increase/decrease in this report y-o-y (+,-) Operating revenue (RMB) 33,163,091,887.39 27,169,940,188.52 22.06% Net profit attributable to shareholders of 741,445,013.25 643,451,580.59 15.23% the listed Company (RMB) Net profit attributable to shareholders of the listed Company after deducting non- 720,954,408.22 627,017,019.45 14.98% recurring gains and losses (RMB) Net cash flow arising from operating 1,229,373,283.57 1,438,204,043.35 -14.52% activities (RMB) Basic earnings per share (RMB/Share) 1.73 1.50 15.33% Diluted earnings per share (RMB/Share) 1.73 1.50 15.33% Weighted average ROE 5.22% 4.91% Increase 0.31 percentage points Increase/decrease in this End of current period End of last period report-end over that of last period-end (+,-) Total assets (RMB) 44,190,878,403.95 39,594,533,471.65 11.61% Net assets attributable to shareholder of 14,346,870,065.79 13,948,322,652.33 2.86% listed Company (RMB) V. Difference of the accounting data under accounting rules in and out of China 1. Difference of the net profit and net assets disclosed in financial report, under both IAS (International Accounting Standards) and Chinese GAAP (Generally Accepted Accounting Principles) □Applicable √ Not applicable The Company had no difference of the net profit or net assets disclosed in financial report, under either IAS (International Accounting Standards) or Chinese GAAP (GenerallyAcceptedAccounting Principles) in the period. 2. Difference of the net profit and net assets disclosed in financial report, under both foreign accounting rules and Chinese GAAP (Generally Accepted Accounting Principles) □Applicable √ Not applicable The Company had no difference of the net profit or net assets disclosed in financial report, under either foreign accounting rules or Chinese GAAP (GenerallyAccepted Accounting Principles) in the period. VI. Items and amounts of extraordinary profit (gains)/loss √Applicable □ Not applicable In RMB Item Amount Note Gains/losses from the disposal of non-current asset (including the Mainly probability of gain and -802,029.11 losses from the end of lease. write-off that accrued for impairment of assets) Governmental subsidy calculated into current gains and Mainly probability of exemption losses(while closely related with the normal business of the 35,363,341.68 and other government grants for Company, excluding the fixed-amount or fixed-proportion special purpose and finance governmental subsidy according to the unified national standard) Discount. Investment costs while acquiring subsidiaries, joint ventures and associated enterprise, less than fair value of the identifiable net 578,610.41 assets from invested enterprise which should be enjoined Switch back of provisi